Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Crunch time for Bristol’s TIGIT bet
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
The Revolution is here, and it’s... confusing
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
